Ligand currently has multiple unpartnered programs available for out-licensing in addition to our Captisol, OmniAb, LTP and HepDirect technologies which are available to partners that could benefit from formulation, antibody discovery or other early stage drug targeting and development expertise.
Granulocyte colony stimulating factor (GCSF) acts on its receptor to stimulate the differentiation of bone marrow hematopoietic cells to form neutrophils.
Ligand is developing a novel Captisol® formulation of Busulfan for use as a conditioning agent prior to hematopoietic stem cell transplantation.
Captisol-enabled® Sertraline (LGD-953) is designed to be the potential first aqueous oral solution to meet the growing demand for better liquid antidepressants for elderly and pediatric patients who are the least able to ingest pills.
Ligand is developing a Captisol-enabled™ injectable formulation of the antihistamine cetirizine to provide rapid onset to treat acute, life-threatening, allergy symptoms.
Ligand is developing novel Captisol-enabled™ silymarin composition for application in the topical sun damage and anti‐aging premium skin-care markets.
FMS-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase with an important role in hematopoietic progenitor cell development.
Glucokinase (GKA) is an enzyme that facilitates removal of glucose in circulation and functions as a glucose sensor mainly in the liver and pancreas cells.
Chemokine receptor 1 (CCR1) is a receptor on the surface of various immune cells (e.g. monocytes and T-cells) that bind multiple chemokines and directly mediates inflammatory responses through leukocyte chemotaxis and cytokine balance.
